Research in pharmaceutical sciences · 2026
Comparative evaluation of microfluidic-synthesized nano-niosomes versus liposomal and micro-niosomal deferoxamine in murine iron overload models.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bazi Ali, Karami-Mohajeri Somayyeh, Valandani Hajar Mardani, Jafari Elham, Oroojalian Fatemeh, Pardakhty Abbas, Khalilabadi Roohollah Mirzaee
Аннотация
BACKGROUND AND PURPOSE: Microfluidic technology provides enhanced standardization for formulating nanoencapsulated drugs compared to traditional bulk methodologies. Here, microfluidic nano-niosomal deferoxamine (Nn-DFO) was compared to micro-niosomal (Mn-DFO) and liposomal (L-DFO) formulations synthesized by conventional thin-film hydration.
EXPERIMENTAL APPROACH: The formulations were subjected to physicochemical analyses. In vivo functional efficacy and safety were analyzed in mouse models of iron overload. Urinary and fecal iron excretion were also assessed.
FINDINGS/RESULTS: Mean particle sizes were 180.89±74.34 nm for L-DFO, 87.06±2.67 nm for Nn-DFO, and 7.41 ± 0.19 μm for Mn-DFO. Encapsulation efficiencies of L-DFO, Nn-DFO, and Mn-DFO formulations were 64.54%, 57.1%, and 70.72%, respectively. The 4-h drug release rates for L-DFO, Nn-DFO, and Mn-DFO formulations were 20.95%, 31.34%, and 26.30%, respectively, compared to 59.46% release from free DFO (F-DFO) within 4 h. Animals treated with F-DFO, L-DFO, Nn-DFO, and Mn-DFO showed significant reductions in the iron content of the liver (45.03%, 49.36%, 41.63%, and 23.52%, respectively). Urinary iron excretion on day 1st and fecal iron excretion on day 3rd after drug administration were the highest in the groups treated with F-DFO and Nn-DF O compared to other groups. Fecal iron excretion on day 7th was the highest in mice receiving Nn-DFO compared to different formulations.
CONCLUSION AND IMPLICATIONS: Nn-DFO synthesized by the microfluidic approach showed iron chelation efficacy and immediate iron excretion profile comparable to F-DFO, while being superior to Mn-DFO and L-DFO regarding delayed iron excretion.
EXPERIMENTAL APPROACH: The formulations were subjected to physicochemical analyses. In vivo functional efficacy and safety were analyzed in mouse models of iron overload. Urinary and fecal iron excretion were also assessed.
FINDINGS/RESULTS: Mean particle sizes were 180.89±74.34 nm for L-DFO, 87.06±2.67 nm for Nn-DFO, and 7.41 ± 0.19 μm for Mn-DFO. Encapsulation efficiencies of L-DFO, Nn-DFO, and Mn-DFO formulations were 64.54%, 57.1%, and 70.72%, respectively. The 4-h drug release rates for L-DFO, Nn-DFO, and Mn-DFO formulations were 20.95%, 31.34%, and 26.30%, respectively, compared to 59.46% release from free DFO (F-DFO) within 4 h. Animals treated with F-DFO, L-DFO, Nn-DFO, and Mn-DFO showed significant reductions in the iron content of the liver (45.03%, 49.36%, 41.63%, and 23.52%, respectively). Urinary iron excretion on day 1st and fecal iron excretion on day 3rd after drug administration were the highest in the groups treated with F-DFO and Nn-DF O compared to other groups. Fecal iron excretion on day 7th was the highest in mice receiving Nn-DFO compared to different formulations.
CONCLUSION AND IMPLICATIONS: Nn-DFO synthesized by the microfluidic approach showed iron chelation efficacy and immediate iron excretion profile comparable to F-DFO, while being superior to Mn-DFO and L-DFO regarding delayed iron excretion.